The Obesity Drug Revolution: New Frontiers in Pharmacotherapy.

Obesity is the most prevalent condition in high-income nations, primarily associated with increased risk of diabetes, cardiovascular disease (CVD), hypertension, and hyperlipidemia. Lifestyle modifications are a key determinant in non-pharmacological management that includes a combination of nutritional therapy, a low-calorie diet, and exercise. Earlier, anti-obesity drugs had been withdrawn from the market due to their safety profiles with cardiovascular and neuropsychiatric toxicity. The current FDA-approved pharmacotherapy consists of orlistat, setmelanotide, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide. Among these, semaglutide has a better clinical and regulatory profile with the feasibility of dosing and frequency. Orforglipron, a non-peptide oral glucagon-like peptide-1 receptor agonist, offers parenteral efficacy with convenient dosing. Probiotics, prebiotics, and fecal microbiota transplantation promote moderate weight loss by regulating metabolism and inflammation. Mitochondrial uncouplers help energy utilization rather than appetite regulation, which focuses on metabolic efficiency. A few challenges in obesity management are financial barriers, weight-promoting medications, inadequate obesity training, discomfort with prescribing, and lack of reimbursement. Innovative therapeutic approaches, multidisciplinary care, and a patient-centered plan are required for better clinical outcomes. This review highlights the current and emerging therapies designed to enhance long-term outcomes in obesity care.